A needle is a single-use instrument
For licensed products the in-use period is established by stability data. For a peptide reconstituted at home there is no such data, and the honest answer is that nobody…
Archive — February 2024
Page 3 of 5 of this archive, newest first.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a SSA exenatide lot at 97.3%, against 93.3% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Wuhan export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The 24-day notice: how a compounding wind-down works in Japan
The document is four pages. Three of them are about dates.
Why the bone question is harder than the muscle question
What the Journal would want measured before treating this as settled in either direction.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
SURMOUNT-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to South Korea after 6 consecutive customs detentions
The route did not close because of a rule about peptides.
Severity grading, and the gap between a grade and an experience
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Oxidation, and the peroxide that came in with the surfactant
The sequence predicts the failure mode. A methionine predicts oxidation; an asparagine followed by a glycine predicts deamidation; a cysteine predicts disulphide scrambling.
What a 40% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
The United Kingdom caps exenatide prescribing to 20 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Zhuhai: 18 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
Reading the semaglutide composition data without the press release
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
Specification and result are two columns, and only one of them is a measurement
Statements of conformity are supposed to rest on a stated decision rule. Almost nothing in this trade states one.
FLOW misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Norway declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to Australia after 19 consecutive customs detentions
The route did not close because of a rule about peptides.
What happens when the drug is taken away: three randomised answers
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
What a 7% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Halvard & Pike Apothecary of Portland, Maine closes after 13 years
A proper account of an operation that existed, and of what closing it cost.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
What high resolution actually buys you
Parts per million sound impressive until they are converted into daltons at the molecular weight of the thing being measured.
Sixteen daltons: methionine, and the easiest degradation to find
Deamidation adds 0.98 daltons. On a low-resolution instrument at incretin molecular weights, that is inside the noise.
What the cagrilintide schedule assumes about a person it has never met
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The online reseller trading as Adamant Research Supply closes after 19 years
A proper account of an operation that existed, and of what closing it cost.
France declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Qingdao export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Janoshik, Medutest, PeptideMeter, VendorInvestigate: a capability audit
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
Seasonal use, holiday use, and the honest state of the evidence
What the exposure arithmetic says about a fortnightly schedule, and where the arithmetic stops being informative.
A supplier suspends shipping to Switzerland after 17 consecutive customs detentions
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Janoshik result on a Qingdao dulaglutide lot lands 3.9 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
What changed at SSA in February, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.